Miscellaneous |
Pressrelease:The market for CNS drugs across the 7MM was worth a substantial $95.5 billion in 2007 www.companiesandmarkets.com adds new report - Commercial Insight - CNS Market Overview - Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors http://www.companiesandmarkets.com/Summary-Market-Report/Commercial-Insight-CNS-Market-Overview-Commercial-dynamics-and-outlook-of-the-neurology,-pain-and-psychiatry-market-sectors-30341.asp Introduction[more] Pressrelease:The continued uptake of existing brands and the launch of two opioid antagonists will cause the market to grow at a compound annual growth rate of 13.5% from 2006 to reach $304m www.companiesandmarkets.com adds new report - Pipeline Insight - Substance Dependence - Part II - Alcohol http://www.companiesandmarkets.com/Summary-Market-Report/Pipeline-Insight-Substance-Dependence-Part-II-Alcohol-30340.asp Introduction[more] Pressrelease:The ALS market was worth $148m in 2006 across the seven major markets www.companiesandmarkets.com adds new report - Pipeline Insight - Orphan Diseases in CNS - Part II - Amyotrophic Lateral Sclerosis http://www.companiesandmarkets.com/Summary-Market-Report/Pipeline-Insight-Orphan-Diseases-in-CNS-Part-II-Amyotrophic-Lateral-Sclerosis-30339.asp Introduction[more] Pressrelease:Deep Brain Stimulation is by far the most common surgical procedure used in the 7MM and neurologists indicated that over 70% of patients receiving it experience both a reduction in PD symptoms and a reduction in the dose of pharmacological medication. www.companiesandmarkets.com adds new report - Stakeholder Insight - Parkinson's Disease - Evidence of neuroprotection essential to progress treatment dynamics http://www.companiesandmarkets.com/Summary-Market-Report/Stakeholder-Insight-Parkinsons-Disease-Evidence-of-neuroprotection-essential-to-progress-treatment-dynamics-30338.asp Introduction[more] Pressrelease:The delayed launch of antipsychotic bifeprunox will impact Solvay's commercial performance over 2006-12 www.companiesandmarkets.com adds new report - Solvay S.A - PharmaVitae Profile http://www.companiesandmarkets.com/Summary-General/Solvay-S.A-PharmaVitae-Profile-30337.asp Introduction This analysis examines the historical and forecast performance for Solvayin the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. Reasons[more] Pressrelease:Servier’s outlook will be shaped primarily by the launch of generic copies of its largest product, Coversyl, in 2007 www.companiesandmarkets.com adds new report - Les Laboratoires Servier - PharmaVitae Profile http://www.companiesandmarkets.com/Summary-General/Les-Laboratoires-Servier-PharmaVitae-Profile-30336.asp Introduction This analysis examines the historical and forecast performance for Servier in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and[more] Pressrelease:Asthma and COPD therapy Spiriva will act as the key driver of Boehringer Ingelheim's commercial performance out to 2012 www.companiesandmarkets.com adds new report - Boehringer Ingelheim GmbH - PharmaVitae Profile http://www.companiesandmarkets.com/Summary-General/Boehringer-Ingelheim-GmbH-PharmaVitae-Profile-30335.asp Introduction This analysis examines the historical and forecast performance for Boehringer Ingelheim in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative[more] Pressrelease:While low-intensity therapies such as Vidaza, Dacogen and Revlimid have improved patient outcomes, higher-risk MDS remains a disease with poor prognosis www.companiesandmarkets.com adds new report - Stakeholder Opinions - Myelodysplastic Syndromes - First approvals spur some interest in a niche market http://www.companiesandmarkets.com/Summary-Market-Report/Stakeholder-Opinions-Myelodysplastic-Syndromes-First-approvals-spur-some-interest-in-a-niche-market-30334.asp Introduction Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders. With a forecast incidence of 36,769 across the seven major markets in 2007, they are one of the most common hematological malignancies. Currently, the only potentially curative option[more] Pressrelease:Pharmaceutical industry ethical sales will increase at a modest 3.2% CAGR 2006 to 2012 www.companiesandmarkets.com adds new report - The Pharmaceutical Company Outlook to 2012 - Strategic Analysis of the Sales Outlook for Big Pharma, Mid Pharma, Japan Pharma and Biotech http://www.companiesandmarkets.com/Summary-Market-Report/The-Pharmaceutical-Company-Outlook-to-2012-Strategic-Analysis-of-the-Sales-Outlook-for-Big-Pharma,-Mid-Pharma,-Japan-Pharma-and-Biotech-30333.asp Introduction[more] Pressrelease:Advances in novel imaging techniques provide opportunities to diagnose and treat the most complex ACS cases www.companiesandmarkets.com adds new report - Stakeholder Insight - Acute Coronary Syndromes - Fresh look at ACS in Europe, what is the real picture http://www.companiesandmarkets.com/Summary-Market-Report/Stakeholder-Insight-Acute-Coronary-Syndromes-Fresh-look-at-ACS-in-Europe,-what-is-the-real-picture-30332.asp Introduction[more] Pressrelease:The UI market is set to continue to grow over the next 6 years, reaching over $2.5 billion in 2012, a 68% increase from 2006 www.companiesandmarkets.com adds new report - Pipeline and Commercial Insight - Urinary Incontinence - Lifecycle management strategies retain mid-term market growth http://www.companiesandmarkets.com/Summary-Market-Report/Pipeline-and-Commercial-Insight-Urinary-Incontinence-Lifecycle-management-strategies-retain-mid-term-market-growth-30331.asp Introduction[more] Pressrelease:10 players in infectious disease account for two thirds of 7 major market chemotherapeutic anti-infective sales by value www.companiesandmarkets.com adds new report - Commercial Insight - Infectious Diseases Overview http://www.companiesandmarkets.com/Summary-Market-Report/Commercial-Insight-Infectious-Diseases-Overview-30330.asp Introduction[more] Pressrelease:Healthcare system characteristics differ greatly between different emerging market countries www.companiesandmarkets.com adds new report - Emerging markets series - Benchmarking key countries Brazil, Russia, India, China and Turkey http://www.companiesandmarkets.com/Summary-Market-Report/Emerging-markets-series-Benchmarking-key-countries-Brazil,-Russia,-India,-China-and-Turkey-30329.asp Introduction[more] Pressrelease:Increased access to the internet has led a growth in physician and patient websites www.companiesandmarkets.com adds new report - eHealthInsight Series - Reaching Doctors and Patients Through New Digital Media http://www.companiesandmarkets.com/Summary-Market-Report/eHealthInsight-Series-Reaching-Doctors-and-Patients-Through-New-Digital-Media-30328.asp Introduction[more] Pressrelease:The global pharmaceuticals market grew by 5.5% in 2007 to reach a value of $577.2 billion. www.companiesandmarkets.com adds new report - Pharmaceuticals - Global Industry Guide http://www.companiesandmarkets.com/Summary-Market-Report/Pharmaceuticals-Global-Industry-Guide-30327.asp Pharmaceuticals: Global Industry Guide is an essential resource for top-level data and analysis covering the pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global,[more] Pressrelease:The global OTC pharmaceuticals market grew by 4% in 2007 to reach a value of $84.8 billion. www.companiesandmarkets.com adds new report - OTC Pharmaceuticals - Global Industry Guide http://www.companiesandmarkets.com/Summary-Market-Report/OTC-Pharmaceuticals-Global-Industry-Guide-30326.asp The OTC Pharmaceuticals: Global Industry Guide is an essential resource for top-level data and analysis covering the OTC pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert[more] Pressrelease:The incidence of bone metastases across these tumor types in the seven major markets is forecasted to total 225,174 in 2008 www.companiesandmarkets.com adds new report - Stakeholder Opinions - Bone Metastases - Impending patent expiries may help make or break newer agents http://www.companiesandmarkets.com/Summary-Market-Report/Stakeholder-Opinions-Bone-Metastases-Impending-patent-expiries-may-help-make-or-break-newer-agents-30325.asp Introduction[more] Pressrelease:The pharmaceutical industry is facing increasingly cost-conscious times, with a declining ROI and numerous blockbuster products facing imminent generic competition www.companiesandmarkets.com adds new report - The Pharmaceutical Industry 2008 - Current and Future Trends and Strategic Issues Shaping Pharma http://www.companiesandmarkets.com/Summary-Market-Report/The-Pharmaceutical-Industry-2008-Current-and-Future-Trends-and-Strategic-Issues-Shaping-Pharma-30324.asp Introduction[more] Pressrelease:Manufacturers are looking to gain greater control over the drug supply chain www.companiesandmarkets.com adds new report - Pharmaceutical Supply chain strategies - Reassessing product distribution to cut costs and improve supply chain management http://www.companiesandmarkets.com/Summary-Market-Report/Pharmaceutical-Supply-chain-strategies-Reassessing-product-distribution-to-cut-costs-and-improve-supply-chain-management-30323.asp Introduction[more] Pressrelease:Wyeth and Elan's bapineuzumab has potential to generate multi-billion dollar revenues, and become one of the most lucrative drugs in medicine. www.companiesandmarkets.com adds new report - Pipeline and Commercial Insight - Alzheimer's Disease - Scenario forecasts reveal vast market potential http://www.companiesandmarkets.com/Summary-Market-Report/Pipeline-and-Commercial-Insight-Alzheimers-Disease-Scenario-forecasts-reveal-vast-market-potential-30322.asp Introduction[more] |
|
|
|
